first glp 1 medication Novo's Wegovy becomes GLP-1 drug approved for MASH List of approved and pending

However, its long-term safety and effectiveness require further investigation

Once-daily liraglutide compared favorably with twice-daily exenatide, with similar improvements in A1C and body weight reductions

doi: 10.3390/ijms21041447

PMC 2928224

Of those three doctors, one said shed take the study with a large grain of salt. Another plainly called it garbage. The companies also pointed to a study showing the importance of exercise in maintaining weight loss, and to data published by one another that has not been peer-reviewedthe Calibrate data on 109 customers, and Emblas tracking of 85 of its GLP-1 users, who it said had maintained a stable body weight for 26 weeks after going off the medication